Form 8-K Angion Biomedica Corp. For: Jun 09
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 9, 2022
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices, including zip code ) | ||||||||
(415 ) 655-4899
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| (Title of each class) | (Trading Symbol) | (Name of exchange on which registered) | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.07. Submission of Matters to a Vote of Security Holders
On June 9, 2022, Angion Biomedica Corp., held its 2022 Annual Meeting of Stockholders. The following is a brief description of each matter voted upon at the Annual Meeting, as well as the final tally of the number of votes cast: (a) for or withheld with respect to the election of directors; and (b) for, against or abstain for the ratification of the appointment of Moss Adams LLP as Angion’s independent registered public accounting firm for the fiscal year ending December 31, 2022. Broker non-votes are also reported. A more complete description of each matter is set forth in Angion’s proxy statement, filed with the Securities and Exchange Commission on April 27, 2022.
Proposal 1: Each of the two directors proposed by Angion for re-election was elected to serve until Angion’s 2025 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified. The tabulation of votes on this matter was as follows:
| Broker | |||||||||||
| For | Withheld | Non-Votes | |||||||||
| Jay R. Venkatesan, M.D. | 12,475,236 | 2,495,011 | 5,689,515 | ||||||||
| Karen J. Wilson | 12,419,646 | 2,550,601 | 5,689,515 | ||||||||
Proposal 2: The appointment of Moss Adams LLP as Angion’s independent registered public accounting firm for the fiscal year ending December 31, 2022, was ratified. The tabulation of votes on this matter was as follows:
| Broker | |||||||||||
| For | Against | Abstain | Non-Votes | ||||||||
| 20,658,864 | 527 | 371 | 0 | ||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ANGION BIOMEDICA CORP. | |||||||||||||||||
| By: | /s/ Jennifer J. Rhodes | ||||||||||||||||
Date: June 13, 2022 | Jennifer J. Rhodes EVP, CBO and General Counsel | ||||||||||||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fluxys hydrogen appointed as “Hydrogen Network Operator” in Belgium
- PMD Device Solutions Publishes 2023 Annual Report
- Apranga Group interim report for 3 months 2024
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
